Close this search box.
Close this search box.

Inito: Helping Women Quickly Track Fertility Hormones in 10 Minutes at Home

Image Credits:
By: Headliners News / November 22, 2023

In the bustling realm of fertility tracking technology, Inito, a Y Combinator alumnus, has marked a significant milestone by securing $6 million in Series A funding, with Fireside Ventures leading the investment charge. The Bengaluru-based startup, founded in 2015 by CEO Aayush Rai and CTO Varun A Venkatesan, both former Siemens professionals, is making waves with its innovative fertility monitor and kit, aiming to revolutionize the at-home fertility tracking experience.

Inito’s fertility monitor and kit offer users a streamlined and user-friendly process for obtaining fertility diagnostic results directly on their smartphones in a mere 10 minutes. The startup’s founders, Rai and Venkatesan, forged their partnership during kayaking sessions, fueled by a shared desire to make a tangible impact on people’s lives. This camaraderie led them to establish Inito, dedicated to crafting tools that empower individuals to manage and comprehend their health from the comfort of their homes.

While traditional at-home ovulation tests primarily focus on estrogen and Luteinizing hormone (LH) to predict fertile days, they often neglect to measure the hormone crucial for confirming ovulation – progesterone metabolite PdG. Inito sets itself apart by measuring not only estrogen and LH but also progesterone metabolite PdG and FSH on a single test strip, providing a comprehensive fertility hormone analysis.

The Inito kit comprises a monitor, test strips, and access to the Inito app. The monitor attaches to the smartphone, reading high-density test strips with precision. Guided by the app, users receive reminders to test on specific days, along with step-by-step instructions. The process involves dipping the test strip in urine, attaching the monitor to the phone, and inserting the test strip for analysis.

In contrast to conventional tests offering binary results, Inito goes a step further, by providing numerical values for fertility hormones and tailoring results to an individual’s body. It not only delineates the full fertile window of six days but also confirms ovulation by examining the rise in progesterone metabolite PdG.

Inito’s approach is underpinned by an app that goes beyond merely presenting hormone values. Their team explained that with all of the latest advancements in AI, they have taken all of this one step further by explaining why a result was given in natural language. The Inito Fertility Monitor has gained FDA registration as a Class-I medical device exempt from premarket notification submission requirements.

Priced at $149, the fertility monitor starter kit includes the device and 15 test strips, with refill strips available for $49. Both products are accessible on Inito and Amazon too.

The recent $6 million funding infusion is earmarked for propelling Inito into more advanced analytics through the integration of AI. With a substantial dataset derived from over 2.5 million tests conducted by Inito users, this amazing startup aims to refine its algorithms, enabling users to correlate symptoms, moods, sleep patterns, and medications with their hormones.

Inito’s expansion plans include making its app available on Android, investing in research and development for new products, and addressing a broader spectrum of healthcare needs beyond fertility. Rai envisions a future where Inito becomes a ubiquitous household presence, offering a variety of tests for health and well-being on a single, accessible device. With a total funding of $15 million to date, Inito is poised to be a transformative force in the intersection of technology and personal healthcare for all around the world.

What do you think?

2 People voted this article. 2 Upvotes - 0 Downvotes.
Please Share This

What do you think?

Show comments / Leave a comment

Leave a reply